Initiation Archives - Page 8 of 272

2 minute read

Affirm’s Growth Prospects Tempered by Valuation and Expense Hurdles: Analyst

April 3, 10:06 AM

Analyst initiates coverage on Affirm Holdings Inc (AFRM) with Hold rating, citing diverse product suite and potential for growth, but flags valuation and stock-based compensation as concerns.

AFRM

2 minute read

Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst

By Vandana Singh

March 28, 2:42 PM

Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key programs utilizing selective myostatin inhibition to

NVO

2 minute read

Western Digital Poised For Breakout, Analyst Sees 10% Estimate Beat And Powerful NAND Recovery

By Anusuya Lahiri

March 27, 3:05 PM

Analyst initiates coverage on WDC with Outperform rating and $80 price target. Expects company to outperform with upcoming split and favorable market conditions.

IDAT

1 minute read

Can CSG Systems Become A Billion Dollar Beacon In A Crowded Tech Market? Analyst Says Yes

By Lekha Gupta

March 27, 2:24 PM

Analyst bullish on CSG Systems' plan to grow to $1.5B by CY/25E, with potential for 2-6% organic growth and M&As driving EPS.

CSGS

2 minute read

DraftKings Gains New Bullish Analyst: ‘We Believe The Earnings Power Of DKNG Is Underappreciated’

By Chris Katje

March 26, 2:54 PM

DraftKings stock could be undervalued and underappreciated based on growth metrics and free cash flow generation, analysts argue.

DKNG

2 minute read

Analysts Eye Summit Therapeutics’ Ivonescimab As Potential Challenger To Merck’s Keytruda in Lung Cancer Treatment

By Vandana Singh

March 26, 2:36 PM

Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expansion worth billions, and a buy rating with $8 target. Updates from Akeso in 2024 and a $5 billion deal add to the optimism, signaling potential share price growth ahead.

MRK

1 minute read

Hilton Grand Vacations To Benefit From Selling Owned Inventory, Analyst Says

By Nabaparna Bhattacharya

March 26, 2:21 PM

Mizuho analyst initiates Hilton Grand Vacations coverage with a Buy rating, foreseeing FY24 EBITDA of $1.24B, citing revenue synergies and owned inventory benefits.

HGV